公开(公告)号：WO2013126904A1

公开(公告)日：2013-08-29

申请号：PCT/US2013/027681

申请日：2013-02-25

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  BRUCKSCHWAIGER, Leopold ,  GUNDINGER, Thomas ,  NUERNBERGER, Julia ,  TESCHNER, Wolfgang ,  SCHWARZ, Hans-peter

Inventor： BRUCKSCHWAIGER, Leopold ,  GUNDINGER, Thomas ,  NUERNBERGER, Julia ,  TESCHNER, Wolfgang ,  SCHWARZ, Hans-peter

IPC: C07K16/06 ,  A61K39/395 ,  A61K35/16 ,  C07K1/30

CPC classification number: A61K39/395 ,  A61K35/16 ,  A61K39/39591 ,  C07K1/145 ,  C07K1/30 ,  C07K16/065

Abstract: Among other aspects, the present invention provides methods for the manufacture of blood protein compositions from pooled plasma. In one embodiment, the invention provides an alcohol fractionation scheme that allows for significant increases in the yield of blood proteins purified from the starting plasma sample. In a specific embodiment, a method for fractionating pooled plasma is provided, the method comprising an initial low pH, high alcohol precipitation step. The present invention also provides pharmaceutical compositions of therapeutic blood proteins.

Abstract translation: 在其它方面中，本发明提供了从合并血浆制造血液蛋白质组合物的方法。 在一个实施方案中，本发明提供了允许从起始血浆样品纯化的血液蛋白的产量显着提高的醇分馏方案。 在一个具体实施方案中，提供了用于分级汇集的等离子体的方法，该方法包括初始低pH，高醇沉淀步骤。 本发明还提供治疗性血液蛋白质的药物组合物。

公开(公告)号：WO2012159700A1

公开(公告)日：2012-11-29

申请号：PCT/EP2012/001768

申请日：2012-04-25

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEAL THCARE S.A. ,  WEBER, Alfred ,  ENGELMAIER, Andrea ,  SCHWARZ, Hans-Peter

Inventor： WEBER, Alfred ,  ENGELMAIER, Andrea ,  SCHWARZ, Hans-Peter

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/68 ,  G01N33/53 ,  G01N2333/8125 ,  G01N2333/966

Abstract: The present invention relates to a method for the measurement of active alpha 1 -proteinase inhibitor (A1PI) in a sample, comprising the steps of binding elastase to a solid support, letting the A1PI contained in the sample bind to the solid phase-bound elastase, and detecting solid phase-bound A1PI with a detection reagent.

Abstract translation: 本发明涉及一种用于测量样品中活性α1-蛋白酶抑制剂（A1PI）的方法，包括以下步骤：将弹性蛋白酶与固体支持物结合，使样品中包含的A1PI与固相结合的弹性蛋白酶结合， 并用检测试剂检测固相键A1PI。

公开(公告)号：WO2011149472A1

公开(公告)日：2011-12-01

申请号：PCT/US2010/036470

申请日：2010-05-27

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  BRUCKSCHWAIGER, Leopold ,  SVATOS, Sonja ,  NÜRNBERGER, Julia ,  TESCHNER, Wolfgang ,  BUTTERWECK, Harald Arno ,  SCHWARZ, Hans-Peter ,  GUNDINGER, Thomas ,  KOELBL, Bernhard ,  GRAUSENBURGER, Reinhard ,  PLJEVLJAKOVIC, Azra

Inventor： BRUCKSCHWAIGER, Leopold ,  SVATOS, Sonja ,  NÜRNBERGER, Julia ,  TESCHNER, Wolfgang ,  BUTTERWECK, Harald Arno ,  SCHWARZ, Hans-Peter ,  GUNDINGER, Thomas ,  KOELBL, Bernhard ,  GRAUSENBURGER, Reinhard ,  PLJEVLJAKOVIC, Azra

IPC: A61K9/08 ,  A61K47/18 ,  A61K9/00 ,  A61K38/17 ,  C07K16/00

CPC classification number: C07K1/36 ,  A61K9/0019 ,  A61K9/08 ,  A61K35/16 ,  A61K38/1709 ,  A61K47/183 ,  C07K1/14 ,  C07K1/18 ,  C07K1/30 ,  C07K1/34 ,  C07K16/065

Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Abstract translation: 本发明提供了用于制造IVIG产品的改进方法。 这些方法提供各种优点，例如在净化期间减少IgG的损失并提高最终产品的质量。 在其它方面，本发明提供适用于静脉内，皮下和/或肌内给药的水性和药物组合物。 在其它实施方案中，本发明提供了治疗疾病或病症的方法，包括施用本文提供的IgG组合物。

公开(公告)号：WO2010065742A1

公开(公告)日：2010-06-10

申请号：PCT/US2009/066588

申请日：2009-12-03

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  VARADI, Katalin ,  ROTTENSTEINER, Hanspeter ,  TURECEK, Peter ,  SCHWARZ, Hans-Peter ,  SCHREINER, Jutta

Inventor： VARADI, Katalin ,  ROTTENSTEINER, Hanspeter ,  TURECEK, Peter ,  SCHWARZ, Hans-Peter ,  SCHREINER, Jutta

IPC: C12Q1/37

CPC classification number: G01N33/86 ,  C12Q1/37 ,  C12Q1/56 ,  G01N33/573 ,  G01N2333/755 ,  G01N2333/96486 ,  G01N2800/224 ,  G01N2800/52

Abstract: [00135] The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo . The invention also relates to methods of using various animal models which demonstrate ADAMTS1 3 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.

Abstract translation: 本发明一般涉及测量切割的血管性血友病因子（VWF）片段的方法。 更具体地，本发明涉及测量具有血小板反应蛋白1型基序，成员13（ADAMTS13）在体内切割VWF的解联蛋白和金属蛋白酶的能力的方法。 本发明还涉及使用表现出与人相似的ADAMTS1 3活性的各种动物模型的方法。 本发明还涉及测量哺乳动物，特别是人和人血浆中rVWF的切割产物的方法。

公开(公告)号：WO2009088876A3

公开(公告)日：2009-12-03

申请号：PCT/US2008088564

申请日：2008-12-30

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  SASGARY MARIA ,  SCHUSTER MARIA ,  SCHWARZ HANS-PETER ,  REIPERT BIRGIT ,  ANTOINE GERHARD ,  EHRLICH HARTMUT

Inventor： SASGARY MARIA ,  SCHUSTER MARIA ,  SCHWARZ HANS-PETER ,  REIPERT BIRGIT ,  ANTOINE GERHARD ,  EHRLICH HARTMUT

IPC: C12N15/85 ,  A01K67/027 ,  A61K49/00 ,  C07K14/745 ,  C07K14/755 ,  C12N9/64 ,  G01N33/50

CPC classification number: C12N15/8509 ,  A01K67/0275 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/02 ,  A01K2267/03 ,  C07K14/745 ,  C07K14/755 ,  C12N9/64

Abstract: The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.

Abstract translation: 本发明一般涉及表达人血液凝固因子如因子VIII，因子VII，因子IX和血管性血友病因子的非人转基因动物的开发。 本发明还提供使用所述转基因动物检测针对人血液凝固因子的免疫原性事件的方法。

公开(公告)号：WO2007134800A1

公开(公告)日：2007-11-29

申请号：PCT/EP2007/004428

申请日：2007-05-17

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  MATTHIESSEN, Peter ,  WEBER, Alfred ,  TURECEK, Peter ,  SCHWARZ, Hans-Peter

Inventor： MATTHIESSEN, Peter ,  WEBER, Alfred ,  TURECEK, Peter ,  SCHWARZ, Hans-Peter

IPC: C07K14/81 ,  A61K38/57

CPC classification number: C07K1/30 ,  A61K38/57 ,  C07K14/473 ,  C07K14/8125

Abstract: The present invention provides methods of preparing alpha- 1 -antiproteinase inhibitor and controlling the amount of des-lys alpha- 1 -antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same.

Abstract translation: 本发明提供了制备α1-蛋白酶抑制剂并控制制剂中des-lysα-1 - 蛋白酶抑制剂的量的方法，以及包含其的组合物以及使用其的治疗方法。

公开(公告)号：WO2005095638B1

公开(公告)日：2006-11-02

申请号：PCT/EP2005003328

申请日：2005-03-30

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  VARADI KATALIN ,  TURECEK PETER ,  KEIL BRIGITTE ,  PEYRER-HEIMSTAETT SYLVIA ,  SCHWARZ HANS-PETER

Inventor： VARADI KATALIN ,  TURECEK PETER ,  KEIL BRIGITTE ,  PEYRER-HEIMSTAETT SYLVIA ,  SCHWARZ HANS-PETER

IPC: C12Q1/56 ,  G01N33/86

CPC classification number: A61K31/66 ,  C12Q1/56 ,  G01N33/86 ,  G01N2333/745

Abstract: The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl 2 . The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

Abstract translation: 本发明提供了一种用于测量患者血液或血浆样品或凝血因子样品中的凝血酶产生的试剂盒。 试剂盒含有冻干组织因子/磷脂复合物和含有凝血酶底物和CaCl 2 2的冻干混合物。 本发明还提供了用于制备试剂盒的试剂的方法。 该试剂盒可以用于测量样品中凝血酶产生的方法，其中可以检测凝血酶产生动力学的变化，例如在将抑制剂旁路剂施用于已经开发出外源凝血因子的抑制剂的患者之后 作为因子VIII。

公开(公告)号：WO2006021314A3

公开(公告)日：2006-03-02

申请号：PCT/EP2005/008467

申请日：2005-08-04

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  ANDERLE, Heinz ,  MATTHIESSEN, Peter ,  SCHWARZ, Hans-Peter ,  TURECEK, Peter ,  KREIL, Thomas ,  BOGGS, Daniel, R.

Inventor： ANDERLE, Heinz ,  MATTHIESSEN, Peter ,  SCHWARZ, Hans-Peter ,  TURECEK, Peter ,  KREIL, Thomas ,  BOGGS, Daniel, R.

IPC: A61L2/10 ,  A61L2/28 ,  G01J1/00 ,  C02F1/32 ,  G01N23/00 ,  G01T1/00

Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivete microorganisms present in a biological fluid, preferably a non-trannsparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.

公开(公告)号：WO9966031A3

公开(公告)日：2001-07-12

申请号：PCT/AT9900154

申请日：1999-06-14

Applicant: BAXTER AG ,  MATTHIESSEN PETER ,  TURECEK PETER ,  SCHWARZ HANS PETER

Inventor： MATTHIESSEN PETER ,  TURECEK PETER ,  SCHWARZ HANS-PETER

IPC: A61K9/19 ,  A61K35/14 ,  A61K38/00 ,  A61K38/46 ,  A61P7/04 ,  C12N9/64 ,  A61K38/36

CPC classification number: C12N9/6437 ,  A61K38/00 ,  C12Y304/21021

Abstract: The invention relates to a preparation based on blood clotting factor VII with a fraction of less than 5 % of factor VIIa, which exhibits a specific activity of at least 50 E/mg and is stable in the absence of blood clotting inhibitors. The invention also relates to a method for producing such a preparation.

Abstract translation: 公开的是基于凝血因子VII与凝血因子Ⅶa的小于5％的比例，其具有的至少50 U / mg的比活性，并在不存在血液凝固抑制剂的稳定性，和其制造方法的准备。

公开(公告)号：WO0027425A3

公开(公告)日：2000-08-31

申请号：PCT/AT9900271

申请日：1999-11-10

Applicant: BAXTER AG ,  SCHWARZ HANS PETER ,  TURECEK PETER ,  BINDER BERND

Inventor： SCHWARZ HANS-PETER ,  TURECEK PETER ,  BINDER BERND

IPC: A61K47/42 ,  A61K38/16 ,  A61K38/36 ,  A61K38/37 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61K38/57 ,  A61P7/04 ,  C12N15/85

CPC classification number: A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  A61K38/16 ,  A61K38/37 ,  A61K38/482 ,  A61K38/57 ,  C12N15/8509 ,  A61K2300/00

Abstract: The invention relates to a pharmaceutical preparation for treating blood-clotting disorders which is characterized in that it contains at least one protein selected from the group of pro-proteins of the blood clotting and additionally contains a coagulation-physiologically inert receptor binding competitor. The invention also relates to the medical application of said preparation.

Abstract translation: 公开的是用于治疗凝血障碍的，其特征在于它含有选自血液凝固的前蛋白组成的组中的至少一种蛋白质和另一种药物制剂包含凝血生理惰性的受体结合的竞争者，以及它们的医疗用途。